Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37595560.
- Also identified by DOI 10.1016/j.cell.2023.07.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Epidermolysis Bullosa Dystrophica
- Genetic Therapy